🇺🇸 FDA
Patent

US 12018259

Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors

granted A61KA61K31/7088A61K38/465

Quick answer

US patent 12018259 (Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K31/7088, A61K38/465, A61P, A61P1/16